Biotech Values

[DewDiligence]

Perhaps PTLA will be worth a look if betrixaban fails and the valuation takes a large hit (assuming the IPO goes through).

You’ll have to wait quite a while to know that—the phase-3 trial reads out in 2H14 (http://www.clinicaltrials.gov/ct2/show/NCT01583218 ).

Actually, Betrixaban is not a bad drug—Portola’s problem is being late to market with an undifferentiated product. Hence, PTLA was forced to test Betrixaban in an indication that is not a natural fit for an oral FXa inhibitor: VTE prevention in acute hospitalized patients (see link above).